Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 54,153 shares of the firm's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $29.90, for a total transaction of $1,619,174.70. Following the transaction, the insider now directly owns 165,650 shares of the company's stock, valued at $4,952,935. The trade was a 24.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.
Soleil Boughton also recently made the following trade(s):
Shares of NYSE HIMS traded up $1.18 during midday trading on Thursday, hitting $30.90. 9,482,037 shares of the company's stock were exchanged, compared to its average volume of 10,299,667. The stock's 50 day moving average price is $27.78 and its 200-day moving average price is $22.03. The firm has a market cap of $6.75 billion, a P/E ratio of 70.22 and a beta of 1.31. Hims & Hers Health, Inc. has a twelve month low of $8.51 and a twelve month high of $35.02.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $401.56 million for the quarter, compared to analysts' expectations of $382.20 million. During the same quarter in the previous year, the company earned ($0.04) earnings per share. The firm's quarterly revenue was up 77.1% compared to the same quarter last year. On average, analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.
HIMS has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a "hold" rating in a research report on Wednesday, November 6th. Needham & Company LLC boosted their target price on shares of Hims & Hers Health from $28.00 to $31.00 and gave the company a "buy" rating in a research note on Monday, January 6th. TD Cowen restated a "buy" rating and set a $28.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Bank of America cut shares of Hims & Hers Health from a "buy" rating to an "underperform" rating and reduced their price objective for the stock from $32.00 to $18.00 in a research report on Thursday, November 14th. Finally, Citigroup cut shares of Hims & Hers Health from a "neutral" rating to a "sell" rating and increased their target price for the company from $24.00 to $25.00 in a research report on Friday, January 10th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, Hims & Hers Health presently has an average rating of "Hold" and a consensus price target of $25.13.
Check Out Our Latest Research Report on HIMS
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ausbil Investment Management Ltd acquired a new position in shares of Hims & Hers Health in the fourth quarter worth $127,000. Genesee Capital Advisors LLC bought a new position in shares of Hims & Hers Health in the fourth quarter valued at approximately $889,000. Perigon Wealth Management LLC acquired a new stake in shares of Hims & Hers Health in the fourth quarter valued at approximately $337,000. Pacer Advisors Inc. acquired a new stake in Hims & Hers Health during the 4th quarter worth $374,000. Finally, KBC Group NV boosted its position in shares of Hims & Hers Health by 107.9% during the fourth quarter. KBC Group NV now owns 8,471 shares of the company's stock worth $205,000 after purchasing an additional 4,396 shares in the last quarter. Institutional investors own 63.52% of the company's stock.
Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hims & Hers Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.
While Hims & Hers Health currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.